Amerique Du Nord S.N.C. San... Net Worth

The estimated Net Worth of Amerique Du Nord S.N.C. San... is at least $18.1 milliard dollars as of 13 October 2010. Amerique San owns over 1,017,401 units of Regeneron Pharmaceuticals stock worth over $18,054,261,002 and over the last 14 years Amerique sold REGN stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Amerique San REGN stock SEC Form 4 insiders trading

Amerique has made over 1 trades of the Regeneron Pharmaceuticals stock since 2010, according to the Form 4 filled with the SEC. Most recently Amerique bought 1,017,401 units of REGN stock worth $28,487,228 on 13 October 2010.

The largest trade Amerique's ever made was buying 1,017,401 units of Regeneron Pharmaceuticals stock on 13 October 2010 worth over $28,487,228. On average, Amerique trades about 1,017,401 units every 0 days since 2010. As of 13 October 2010 Amerique still owns at least 15,816,953 units of Regeneron Pharmaceuticals stock.

You can see the complete history of Amerique San stock trades at the bottom of the page.

What's Amerique San's mailing address?

Amerique's mailing address filed with the SEC is 174, AVENUE DE FRANCE174, AVENUE DE FRANCE, , PARISPARIS, I0I0, 7501375013.

Insiders trading at Regeneron Pharmaceuticals

Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis et Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.

What does Regeneron Pharmaceuticals do?

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.

Complete history of Amerique San stock trades at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals executives and stock owners

Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include:

• P. Roy Vagelos,
  Chairman of the Board, Director
• Leonard Schleifer,
  President, Chief Executive Officer, Director
• George Yancopoulos,
  President, Chief Scientific Officer, Director
• Marion McCourt,
  Senior Vice President - Commercial
• Andrew Murphy,
  Executive Vice President - Research
• Neil Stahl,
  Executive Vice President - Research and Development
• Robert Landry,
  Chief Financial Officer, Executive Vice President - Finance
• Daniel Van Plew,
  Executive Vice President, General Manager - Industrial Operations and Product Supply
• Dr. George D. Yancopoulos M.D., Ph.D.,
  Scientific Founder, Pres, Chief Scientific Officer & Director
• Dr. Leonard S. Schleifer M.D., Ph.D.,
  Founder, Pres, CEO & Director
• Dr. George D. Yancopoulos,
  Scientific Founder, Pres, Chief Scientific Officer & Director
• Robert E. Landry Jr.,
  Exec. VP of Fin. & CFO
• Daniel P. Van Plew,
  Exec. VP and GM of Industrial Operations & Product Supply
• Joseph J. LaRosa,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Andrew J. Murphy,
  Exec. VP of Research
• Arthur Ryan,
  Independent Director
• George Sing,
  Independent Director
• Christine Poon,
  Independent Director
• Michael Brown,
  Independent Director
• Huda Zoghbi,
  Independent Director
• Joseph Goldstein,
  Independent Director
• Bonnie Bassler,
  Independent Director
• N. Anthony Coles,
  Independent Director
• Marc Tessier-Lavigne,
  Independent Director
• Christopher Fenimore,
  Vice President, Controller
• Joseph LaRosa,
  Executive Vice President, General Counsel, Secretary
• Justin Holko,
  VP of Investor Relations
• Bob McCowan,
  Sr. VP of IT & Chief Information Officer
• Gerald Underwood,
  Sr. VP of Technical Operations
• Christopher R. Fenimore,
  Sr. VP, Head of Accounting & Controller
• Patrice Gilooly,
  Sr. VP of Quality Assurance & Operations
• Charles A Baker,
  Director
• Michael S Aberman,
  SVP Strategy Investor Relation
• Sanofi,
  
• Robert J Terifay,
  EVP Commercial
• Alfred G Gilman,
  Director
• Robert Alexander Ingram,
  Director
• Eric M Shooter,
  Director
• Murray A Goldberg,
  SVP Administration & Asst Secr
• Stuart Kolinski,
  SVP General Counsel and Secret
• Amerique Du Nord S.N.C. San...,
  
• Peter Dworkin,
  VP Investor Relations & Commun
• Randall Rupp,
  SVP, Manufuring Operations
• Pharma Ag Novartis,
  10% owner
• Hans Peter Guler,
  VP Clinical Programs
• William Roberts,
  VP Reg Dev & Med Safety
• Peter Powchik,
  SVP Clinical Development & Reg
• Douglas S Mc Corkle,
  VP Controller and Asst Treasur
• Craig B. Thompson,
  Director
• Kathryn Guarini,
  Director
• David P Schenkein,
  Director
• Jason Pitofsky,
  VP Controller